Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Immunity 52

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

52

52

European Pharmaceutical Review

MAY 11, 2023

Novartis shared long-term data for its SMA gene therapy in March 2023, which indicated significant long-term motor-milestone achievements in spinal muscular atrophy (SMA). Without this protein, the motor neuron cells shrink and eventually die. This causes debilitating and potentially fatal muscle weakness. Why is it significant? years post-dosing.

Drug Development 67

Drug Development 67

PharmaShots

MARCH 9, 2023

Present company and time period: Pfizer (2 yrs.) Designation: Chief Medical Officer (CMO) and Head of Worldwide Medical and Safety at Pfizer Previous company: Stanford University (12 yrs. Present company and time period: Sensium Healthcare (6 yrs. Designation: Chief Scientific Officer Previous company: Toumaz UK Ltd. (15

Clinical Pharmacology 40

Clinical Pharmacology Immunity Immunization Pharmaceutical Companies 40